2018, Number 5
<< Back Next >>
Rev Clin Esc Med 2018; 8 (5)
Cardiotoxicidad de los Quimioterapéuticos Diferentes a Antraciclinas de la Lista Oficial de Medicamentos de la Caja Costarricense del Seguro Social
Salas SJ, Pérez CJI
Language: Spanish
References: 41
Page: 1-10
PDF size: 681.17 Kb.
ABSTRACT
Cardio-oncology is a new discipline that looks to
focus on the screening, monitoring and treatment
of patients with cancer that show up with heart
disease during and after their treatment. This
is due to the fact that the cardiotoxic effects
associated to chemotherapeutics is widely known
and backed up with abundant clinical trials.
Nevertheless, it is not until recently that in Costa
Rica the Cardio-oncologic Units were created for
the first time, which now can be found in multiple
medical centers of our public health system.
Up next, we present a summary of the clinical
manifestations of the diverse non-anthracycline
oncologic therapies that are available in the “Caja
Costarricense del Seguro Social”.
REFERENCES
Adão R De Keulenaer G Leite-Moreira A Brás-Silva C. Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. Rev Port Cardiol. 2013; 32(5): 395-409.
2.Lenneman C Sawyer D. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res. 2016; 118:1008-1020.
3.LópezFernández T Thavendiranathan P. Nuevas técnicas de imagen cardiaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos. Rev Esp Cardiol. 2017; 70(6): 487-495.
Plana JC Galderisi M Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 Sep;27(9):911-39.
Tajiri K Aonuma K Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017; 47(8): 678-682.
Plana JC Galderisi M Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27(9):911-39.
Gottdiener JS Appelbaum FR Ferrans VJ Deisseroth A Ziegler J. Cardiotoxicity associated with highdose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758.
Appelbaum F Strauchen JA Graw RG Jr et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet. 1976;1(7950):58.
Quezado ZM Wilson WH Cunnion RE et al. Highdose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993; 118(1):31.
10.Kandylis K Vassilomanolakis M Tsoussis S Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol. 1989; 24(6):395.
11.Huddart RA Norman A Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513.
12.Fung C Sesso HD Williams AM et al. Multi- Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. J Clin Oncol. 2017; 35(11):1211.
13.Perry MC. Effects of chemotherapy on the heart. In: Cancer and the Heart. Kapoor AS (Ed), Springer Verlag, New York. 1986; p.223.
14.Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000; 18(4):299-313.
15.Saif MW Shah MM Shah AR. Fluoropyrimidineassociated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009; 8(2):191.
16.Jensen SA Hasbak P Mortensen J Sørensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol. 2010; 28(36):5280.
17.Kosmas C Kallistratos MS Kopterides P et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008; 134(1):75-82.
18.Yoshida T Araki E Ligo M et al. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol. 1990; 26(5):352-4.
de Forni M Malet-Martino MC Jaillais P et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10(11):1795.
20.Kettunen R Huikuri HV Oikarinen A Takkunen JT. Methotrexate-linked ventricular arrhythmias. Acta Derm Venereol. 1995;75(5):391.
21.Perez-Verdia A Angulo F Hardwicke FL Nugent KM. Acute cardiac toxicity associated with highdose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy. 2005;25(9):1271.
22.Hermans C Straetmans N Michaux JL Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol. 1997; 75(1-2):55.
23.Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002; 95(7):1592.
24.Russell SD Blackwell KL Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416.
25.Millward PM Bandarenko N Chang PP et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion. 2005; 45(9):1481.
26.Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm. 2003;60(15):1531.
27.Cargill RI Boyter AC Lipworth BJ. Reversible myocardial ischaemia following vincristine containing chemotherapy. Respir Med. 1994; 88(9):709.
28.Yancey RS Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep. 1982;66(3):587.
29.Gehl J, Boesgaard M Paaske T Vittrup Jensen B Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996;7(7):687.
30.Malhotra V Dorr VJ Lyss AP et al. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin Breast Cancer. 2004; 5(5):377.
31.Fossella FV Lee JS Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic nonsmall- cell lung cancer. J Clin Oncol. 1994;12(6):1238. 32.Verweij J Funke-Küpper AJ Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother. 1988;5(3):159.
33.Ravry MJ. Cardiotoxicity of mitomycin C in man and animals. Cancer Treat Rep. 1979;63(4):555.
34.White DA Schwartzberg LS Kris MG Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer. 1987;59(9):1582.
35.Vogelzang NJ Frenning DH Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep. 1980;64(10-11):1159.
36.Schecter JP Jones SE Jackson RA. Myocardial infarction in a 27-year-old woman: possible complication of treatment with VP-16-213 (NSC- 141540), mediastinal irradiation, or both. Cancer Chemother Rep. 1975;59(5):887.
37.Yano S Shimada K. Vasospastic angina after chemotherapy with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J. 1996;60(3):185.
38.Kerkelä R Grazette L Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908.
39.Atallah E Durand JB Kantarjian H Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233.
40.Hunt SA Abraham WT Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):391.
41.National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Disponible en: www.nccn.org/ professionals/physician_gls/f_guidelines.asp. Accesado en Marzo 2018.
42.Caja Costarricense de Seguro Social. Lista oficial de medicamentos. 2013. Disponible en www.ccss. sa.cr/lom. Accesado en Marzo del 2018.
Full text